Article and Video CATEGORIES
Tell your story and help us help others!
The application process is now closed. Thank you for your interest!
GRACE Patient Perspectives: Clinical Trials Storytelling Program - 2024-25 - Overview
The goal of this Patient Perspectives program is to give a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. By telling your story, you can educate others on the process, discuss your difficulties, and share your accomplishments. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. This is a paid opportunity and you will receive a stipend for your participation!
Storytelling will take the form of written, video, and/or audio/podcast to reach the largest audience. GRACE staff will coach and support participants on digital outreach and advocacy.
All people currently enrolled in, or with past enrollment in, a clinical trial for a cancer diagnosis are welcome and encouraged to apply. GRACE’s designated committee will review the nominees and select up to 3 applicants for participation in the 2024-25 program.
Who is GRACE?
The Global Resource for Advancing Cancer Education (GRACE, cancerGRACE.org) is a non-profit organization founded by leading Thoracic Oncologist, Dr. Howard (Jack) West, in 2007. GRACE’s mission is to provide expert-mediated information directly to people with a cancer diagnosis and their caregivers to empower them to become direct partners in their cancer treatment. We currently produce over 300 short videos each year, reaching our community in over 190 countries.
Benefits of Participation
Applicants selected for this year’s program will work closely with GRACE staff to develop new educational content and learn new communication skills through the storytelling process.
Participants will receive training on digitally distributed content, social media, and other platforms. Participants' work will be highlighted and shared by GRACE, our network of established leaders in the oncology community, and GRACE board members with an array of interests and connections.
Participants will receive a stipend, training in communication and media platforms and a tech ‘package’.
Expectations
Participants will work with GRACE to develop program formats and production and will present a proposal based on their experience in a clinical trial program. Participants will be expected to attend (via ZOOM) regular meetings throughout the program year to learn and to discuss their ideas. A minimum of three (3) media productions per participant will be expected by the end of the program.
Ideal Candidates
People who are navigating a cancer diagnosis, who are currently or have been involved in a clinical trial, and who have a passion for helping others and telling their stories are ideal for this program.
Applicants should have a particular interest and passion for communications, sharing experiences, storytelling, and patient education. People looking for a way to give back to the cancer community, who exhibit strong written and oral communication skills coupled with a passion for sharing experiences to educate and advocate will thrive in this program. GRACE will guide them through boosting their voice to advocate for themselves and others in the cancer community.
2024 is our fourth year for this program, and we are excited to continue to generate a platform for patient advocacy and sharing patient education in the area of clinical trials.
The application due date has been extended to October 25, 2024 for consideration. Applicants will be contacted by November 8, 2024, with information regarding acceptance and the next steps.
To apply online please click here OR download the above attached pdf form and email it to dbrock@cancerGRACE.org.
Any questions, please contact Denise Brock at dbrock@cancergrace.org or 888-501-1025 x2.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,